Press Releases and Blog
Blog
Business Groups and Employers Express Support for Preserving Their Contracting Flexibility
In case you missed it, business groups and individual employers from across the country signed the below letter to Congress expressing support for preserving their
Bank Of America Survey Confirms Pharmacy Benefit Market Is Competitive, Transparent, And Delivering Value For Employers
Bank of America (BofA) recently released the findings of an employer survey that found that the pharmacy benefit marketplace is highly competitive, confirmed that surveyed
Employers Hire Pharmacy Benefit Companies To Manage Growing Rx Drug Costs
Fact: Employers are under no obligation to hire pharmacy benefit companies, but a vast majority of employers work with pharmacy benefit companies. Recent findings from
New PCMA Rx Research Corner Blog: A World Without PBMs: A Lesson From Economics
In case you missed it, the Pharmaceutical Care Management Association (PCMA) released a new Rx Research Corner blog, by Vice President of Research Amanda Frost,
ICYMI: Prescription Prices Should Be Addressed At BIO International Convention
In case you missed it, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA), discusses how the BIO International
Webinar Highlights Big Pharma’s Rising Launch Prices and Cost-Saving Value of Pharmacy Benefit Companies
Last month, the IQVIA Institute held a webinar, “The Use of Medicines in the U.S. 2023.” Panelists highlighted how big drug companies set the price of
Press Releases
New PCMA Podcast Highlights Importance of PBMs
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, today released a new episode, “The Importance of PBMs in Health Care Costs,” which highlights the
PCMA Statement on the Senate Finance Committee Hearing on Prescription Drug Prices in Medicare
(Washington D.C.) – Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s Senate Finance Committee hearing, “Prescription Drug Price Inflation:
PCMA Statement on the Pre-Approval Information Exchange Act
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement on H.R. 7008, the Pre-approval Information Exchange (PIE) Act:
PCMA Applauds Passage of Postal Service Reform Act
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the passage of the Postal Service Reform
Medicare Part D 2023 Proposed Rule Could Increase Costs
New Milliman Analysis Shows Medicare Part D Proposed Rule Could Increase Premiums More than It Saves in Cost Sharing for Majority of Beneficiaries (Washington, D.C.) —
Rite Aid’s PBM Elixir Joins the Pharmaceutical Care Management Association
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that Elixir, Rite Aid’s pharmacy benefit manager (PBM) business, is joining the trade association.
Wide Array of Community Leader Voices Oppose Legislation, S. 127, Expanding FTC Power to Pick Winners and Losers
A wide array of voices from across the country are calling on lawmakers to oppose recently reintroduced legislation, the Pharmacy Benefit Manager Transparency Act (S.127),
WATCH NOW: Prescription for Change: Improving Competition to Lower Drug Prices
In a new web video, Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott discusses the critical role and value of pharmacy benefit companies,
Policymakers, Drug Pricing and Economic Experts Highlight Importance of Greater Competition to Lower Drug Prices
Conversation on “Improving Competition to Lower Drug Prices” Emphasizes Need to Stop Abuse of the Patent System Last week, The Hill hosted an event titled, “Prescription for Change:
Legislation Targeting REMS Abuse Adds to Bipartisan Action on Solutions to Boost Competition and Lower Prescription Drug Costs
Lawmakers Reintroduce Bill to Close Loopholes Allowing Big Drug Companies to Block Competition from More Affordable Options The Pharmaceutical Care Management Association, PCMA, applauds Senators
Pharma Boardroom: Washington Must Remain Focused on Root Cause of High Drug Prices
For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them,
ICYMI: Webinar Highlights How Introduction of More Biosimilars to U.S. Market Will Encourage Competition and Lower Prescription Drug Costs
New Paper Finds Potential Cost Savings from Adalimumab Biosimilars are Significant but Competitive Market Will Take Time The Pharmaceutical Care Management Association (PCMA) agrees that
ICYMI: Economic Experts Agree Anti-Competitive S. 127 Would Increase Rx Drug Costs and Give FTC Unprecedented Authority to Pick Winners and Losers
Misguided Legislation Targets Pharmacy Benefits That Save Employers and Patients an Average of $1,000 Per Person Each Year and Undermines Market Forces in Health Care
What They Are Saying: Lawmakers, Health Care Experts, and Drug Pricing Advocates Support Competition and End to Patent Abuse
Lawmakers, health care experts, and drug pricing advocates agree that big drug companies block competition, are responsible for setting and increasing prices, and must be
ICYMI: Health Care Economist Estimates S.127 Would Increase Federal Deficit by “Tens of Billions of Dollars”
Casey Mulligan, Ph.D., professor of economics at the University of Chicago, member of the National Bureau of Economic Research (NBER), and former Chief Economist of the White House Council of Economic Advisers, testified before the U.S. Senate Committee on Commerce, Science, and Transportation during a hearing Thursday on S. 127.
ICYMI: PCMA Releases Policy Roadmap to Unlock an Affordable Health Care Future for Patients
Pharmacy Benefit Companies Ready to Work with Policymakers on Solutions to Build a More Competitive, Sustainable, and Affordable Prescription Drug Marketplace
